About

Robert Azelby has served as a member of ADC Therapeutics' board of directors since June 2023. From October 2020 to February 2023 he was President and Chief Executive Officer of Eliem Therapeutics, and previously Chief Executive Officer of Alder BioPharmaceuticals until its 2019 acquisition by H. Lundbeck, and Executive Vice President, Chief Commercial Officer of Juno Therapeutics; earlier he held various positions at Amgen, including vice president and general manager, oncology. He currently serves on the boards of Autolus Therapeutics, Cardinal Health and Terns Pharmaceuticals. Mr. Azelby holds a B.A. in Economics and Religious Studies from the University of Virginia and an M.B.A. from Harvard Business School.

Roles

ADC Therapeutics SA
Director · Current role
June 2023–present
Eliem Therapeutics
President and Chief Executive Officer
October 2020 - February 2023
Alder BioPharmaceuticals
Chief Executive Officer
June 2018 - 2019
Juno Therapeutics
EVP, Chief Commercial Officer
November 2015 - May 2018
Amgen
VP and GM, Oncology and other roles
—

External Roles

Autolus Therapeutics
Director
—
Cardinal Health
Director
—
Terns Pharmaceuticals
Director
—

Director Compensation

FY 2025
Fees earned or paid in cash
$67,500
ComponentAnnual cash retainer plus committee and leadership retainers earned in fiscal 2025
Stock awards
$143,600
ComponentAnnual RSU grant, ASC 718 grant-date fair value
Total
$211,100

Also at ADC Therapeutics SA

Related

See how Top Bucket AI works for your firm

Request Demo
Top Bucket AI Research

Stay ahead of private markets

Research and market intelligence for private-markets professionals.

✓

You're subscribed.

Thanks for signing up.